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Introduction
To understand disease mechanism and close the gap
between genotype and phenotype, majority of studies
today use the high-throughput methods that allow us to
study genes on a global scale. One of these methods is
expression profiling which generates a “snapshot” of cellu-
lar activity at the time of analysis, telling us exactly what
processes are occurring. By comparing disease and control
samples it is possible to elucidate the processes contribut-
ing to disease and how they are altered. To date a number
of disparate expression profiling studies in patients diag-
nosed with spondyloarthritis (SpA) have been undertaken,
but results of these studies were often inconsistent. To the
best of our knowledge, there has been no expression pro-
filing study with RNA isolated from whole blood in a
cohort of patients diagnosed with juvenile spondyloarthri-
tis (jSpA) using ILAR criteria for enthesitis related arthritis
(ErA), with known HLA genotype and calculated odds
ratio (OR) for disease development. Further on, there was
no study in which expression of selected genes was inde-
pendently confirmed in new cohorts of untreated and trea-
ted patients diagnosed with jSpA, as well as with other
forms of juvenile idiopathic arthritis (JIA).
Objectives
The aim of the present study was to identify and con-
firm gene signatures and novel biomarkers in various
cohorts of untreated and treated patients diagnosed with
jSpA and other forms of JIA.
Methods
Total RNA was isolated from whole blood of 45 children
with known HLA genotype, calculated odds ratio for
disease development and diagnosis of jSpA according to
ILAR criteria, 11 children with oligo- and polyarticular
forms of JIA, as well as 12 age and sex matched control
participants without diagnosis of chronic inflammatory
disease. DNA microarray gene expression with Affymetrix
GeneChip was performed in 11 patients with jSpA and in
four healthy controls, along with bioinformatics analysis of
retrieved data (DAVID, GSEA, IPA). Carefully selected dif-
ferentially expressed genes (TLR4, NLRP3, PTPRN2,
CXCR4, DUSP6, TNFSF4, MAP2K2, MAPKBP1, MYST3,
PTPN12) where analyzed by qRT-PCR in all study
participants.
Results
Microarray results and bioinformatics analysis revealed
745 differentially expressed genes involved in processes
such are antigen recognition and activation of immuno-
logical response, migration of inflammatory cells and
regulation of the immune system. qRT-PCR analysis of
selected genes confirmed data universality and specificity
of expression profiles in jSpA patients.
Conclusion
The present study has identified differences in the
expression of genes related to various processes respon-
sible for jSpA development. Among these, the genes of
highest importance, which showed consistent expression
in study patients diagnosed with jSpA, were TLR-4 and
NLRP3, which can lead to the development of systemic
autoimmunity, as well as CXCR4 and PTPN12, which
can drive other processes important for pathophysiology
of jSpA. We strongly believe that our results represents
an important step toward a better understanding of the
molecular mechanisms and complex pathophysiology of
jSpA, while highlighted genes and their products could
have a prognostic value and potential therapeutic use.
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